Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortizatization of Intangibles (2016 - 2023)

Historic Amortizatization of Intangibles for Seres Therapeutics (MCRB) over the last 8 years, with Q2 2023 value amounting to $49000.0.

  • Seres Therapeutics' Amortizatization of Intangibles rose 12094.02% to $49000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $49000.0, marking a year-over-year increase of 12606.38%. This contributed to the annual value of $236000.0 for FY2023, which is 13430.23% up from last year.
  • Per Seres Therapeutics' latest filing, its Amortizatization of Intangibles stood at $49000.0 for Q2 2023, which was up 12094.02% from $187000.0 recorded in Q1 2023.
  • Seres Therapeutics' 5-year Amortizatization of Intangibles high stood at $1.6 million for Q4 2021, and its period low was -$851000.0 during Q1 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was -$12000.0 (2022), whereas its average is -$87400.0.
  • In the last 5 years, Seres Therapeutics' Amortizatization of Intangibles surged by 46666.67% in 2019 and then plummeted by 1730000.0% in 2021.
  • Seres Therapeutics' Amortizatization of Intangibles (Quarter) stood at $85000.0 in 2019, then tumbled by 748.24% to -$551000.0 in 2020, then skyrocketed by 390.2% to $1.6 million in 2021, then tumbled by 100.75% to -$12000.0 in 2022, then skyrocketed by 508.33% to $49000.0 in 2023.
  • Its Amortizatization of Intangibles stands at $49000.0 for Q2 2023, versus $187000.0 for Q1 2023 and -$12000.0 for Q4 2022.